Has Kaveh Ehsanipoor, MD received payments from drug or device companies?

Yes. Drug and device makers reported $76,115 in general payments to Kaveh Ehsanipoor, MD across 645 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kaveh Ehsanipoor, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kaveh Ehsanipoor, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kaveh Ehsanipoor, MD

Endocrinology, Diabetes & Metabolism · Savannah, GANPI 1821037706

Payments from drug & device makers

$76,115in general payments, 2019–2025

Across 645 payments — averaging $118.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$35K
AstraZeneca$32K
Lilly USA, LLC$1K
Novo Nordisk$1K
Mannkind Corporation$572
Sanofi-aventis U.S. LLC$556
plus $5K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	106	$34,867
AstraZeneca(2 entities)	76	$32,046
Lilly USA, LLC	76	$1,488
Novo Nordisk	63	$1,092
Mannkind Corporation	20	$572
Sanofi-aventis U.S. LLC	28	$556
Radius Health, Inc.	12	$465
AbbVie	19	$294
Dexcom, Inc.	13	$260
Boehringer Ingelheim	14	$256
Lundbeck LLC	11	$246
Johnson & Johnson	15	$234
Bayer	11	$207
Idorsia Pharmaceuticals US Inc	10	$207
Novartis	16	$202
Xeris Pharmaceuticals, Inc.	10	$201
Antares Pharma, Inc.	12	$187
Valeritas, Inc.	5	$178
BETA Bionics, Inc.	3	$174
Insulet Corporation	8	$150
Merck	9	$142
Medtronic(2 entities)	7	$134
Otsuka America Pharmaceutical, Inc.	6	$125
Vivus LLC	8	$115
Cequr Corporation	2	$106
Janssen Scientific Affairs, LLC	1	$105
Exact Sciences	7	$105
Amarin Pharma, Inc.	6	$104
IBSA Pharma Inc.	6	$101
Tandem Diabetes Care, Inc.	4	$72
Madrigal Pharmaceuticals	3	$70
Pfizer	4	$68
Corcept Therapeutics	3	$66
Ironwood Pharmaceuticals, Inc	3	$66
Zealand Pharma US, Inc.	3	$64
Kowa Pharmaceuticals America, Inc.	5	$64
Esperion Therapeutics, Inc.	3	$61
Regeneron Healthcare Solutions, Inc.	3	$59
Vistapharm, Inc.	2	$47
Pulmonx Corporation	1	$45
Phathom Pharmaceuticals, Inc.	4	$39
Ultragenyx Pharmaceutical Inc.	2	$38
BD	2	$36
Senseonics, Incorporated	2	$31
Recordati_rare_diseases_inc.	1	$30
Endo Pharmaceuticals Inc.	2	$28
Currax Pharmaceuticals LLC	2	$28
Boston Scientific	1	$24
Scynexis, Inc.	1	$23
Shield Therapeutics Inc	1	$22
VBI Vaccine (delaware) Inc.	1	$22
Sumitomo Pharma America, Inc.	1	$21
GSK	1	$19
Abiomed	1	$18
Nalpropion Pharmaceuticals LLC	1	$17
Baxter Healthcare	1	$17
Sanofi Pasteur Inc.	1	$16
Shire North American Group Inc	1	$16
Amneal Pharmaceuticals LLC	1	$15
Avanir Pharmaceuticals, Inc.	1	$14

How this compares

$76,115 in reported general payments places this provider in the 85th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia →

Medicare billing

Part B allowed, 2024

$43,099

Medicare patients

190

Services billed

533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Savannah

Ismary DecastroSavannah$169K
Joseph DehavenSavannah$58K
Carolyn NelsonSavannah$25K
James StoeverSavannah$11K
Bruce BodeAtlanta$18.3M
Gulliermo UmpierrezAtlanta$6.6M
John ReedRoswell$5.7M
Thomas JonesMacon$4.8M
Steven LeichterColumbus$3.1M
Jason BernerJasper$2.6M

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →